ULBP2 and hepatocellular carcinoma: Preclinical studies have shown that cisplatin inhibits the androgen receptor (AR) in hepatocellular carcinoma cells by upregulating miR-34a-5p and altering ubiquitination, which activates UL16-binding protein 2 (ULBP2) signaling, promotes infiltration and activation of NK cells, and inhibits tumor progression [88].